MSF hits out at Pfizer's 'tiny' price reduction on Prevenar 13 in developing countries
US pharma giant Pfizer (NYSE: PFE) has announced commitments to reduce the price of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine (PCV), 13 – valent, absorbed) in the world’s poorest countries.
The price reduction has not been warmly received by all, however, with humanitarian organization Médecins Sans Frontières criticizing the “tiny” price reduction as “inadequate.”
This commitment has been undertaken through GAVI, a private-public global health partnership working to increase immunization in resource-limited countries, and was announced in GAVI’s pledging conference in support of its 2016-2020 strategy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze